Clinical trials: Antipsychotic
Schizophrenia
MedActive: A Smartphone Intervention to Improve Adherence to Antipsychotic Medications
We propose to develop and pilot test the effect of a mobile smartphone intervention, MedActive, on improving antipsychotic adherence among individuals with schizophrenia.
- Trial name
- NCT01953237
- Testing
- MedActive, Smartphone
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia
The purpose of this study is to investigate the effects of flexibly dosed Brexpiprazole monotherapy in the improvement of early-episode schizophrenia through the assessment of social functioning, efficacy, and tolerability.
- Trial name
- NCT02013622
- Testing
- Brexpiprazole
- Where
- 22 sites in United States
- Volunteers
- 49 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia
The purpose of this study is to explore changes in efficacy, cognitive functioning, and safety of flexibly-dosed Brexpiprazole monotherapy in subjects with acute schizophrenia
- Trial name
- NCT02054702
- Testing
- Brexpiprazole, Aripiprazole
- Volunteers
- 97 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
A study to evaluate the efficacy and safety of two atypical antipsychotics vs. placebo in patients with an acute exacerbation of either schizophrenia or schizoaffective disorder
- Trial name
- NCT00061802
- Testing
- risperidone, quetiapine
- Where
- 13 sites in United States, India and 1 more
- Volunteers
- 225 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
The Effect of a Weight Management Program During Treatment With Olanzapine
The study is a prospective, randomized, open-label study.
- Trial name
- NCT00169702
- Testing
- weight management program
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Schizophrenia
The Effect of a Community-based LAT-treated Management Model on the Violence Risk of Patients With Schizophrenia
This is a 49 weeks open-label randomized controlled study. Patients with schizophrenia and violence risk will be enrolled in the study.
- Trial name
- NCT03434210
- Testing
- LAT-treated Community Model, care as usual
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Yi Li MD, PhD
Schizophrenia
Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With Schizophrenia
The purpose of this study is to evaluate efficacy, safety and tolerability of flexible, once-daily doses of paliperidone extended-release (ER) in patients with schizophrenia from Argentina and Colombia that previously failed…
- Trial name
- PERFLEX (NCT01724359)
- Testing
- Paliperidone ER
- Where
- 5 sites in Argentina, Colombia
- Volunteers
- 95 people
- Sponsor
- Janssen-Cilag, S.A.
Behavioral and Psychiatric Symptoms of Dementia
The Use of Antipsychotics in the Program of All-inclusive Care for the Elderly (PACE)
The aim of this study is to retrospectively evaluate and describe the use of antipsychotics among participants enrolled in the Program of All-inclusive Care for the Elderly (PACE), a community-based practice setting.
- Trial name
- NCT03692182
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Tabula Rasa HealthCare
Weight Gain
Effects of Modafinil on Olanzapine Weight Gain
This study is designed as a 3 week, randomized, double blind, placebo controlled, trial. Olanzapine and modafinil will be titrated to 10mg and 200mg respectively.
- Trial name
- NCT00636896
- Testing
- Olanzapine plus modafinil
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Neuropsychiatric Research Institute, Fargo, North Dakota
Schizophrenia
Safety and Efficacy of Cariprazine in Schizophrenia
The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.
- Trial name
- NCT01104779
- Testing
- Cariprazine
- Where
- 41 sites in United States, Colombia and 2 more
- Volunteers
- 446 people
- Sponsor
- Forest Laboratories
Schizophrenia, Metabolic Syndrome
The Influence of Vitamin D on Atypical Antipsychotic-induced Weight Gain
Schizophrenia and bipolar disorders are major public health problems. The second generation anti-psychotic drugs have efficacy for both positive and negative symptoms and a favorable risk profile as far as movement disorders.
- Conditions
- Schizophrenia, Metabolic Syndrome, Vitamin D Deficiency
- Trial name
- NCT02281162
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Creighton University
Schizophrenia
A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)
This randomized, multi-center, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with sub-optimally controlled symptoms of schizophrenia.
- Trial name
- NCT01235585
- Testing
- bitopertin [RO4917838]
- Where
- 120 sites in United States, Brazil and 12 more
- Volunteers
- 597 people
- Sponsor
- Hoffmann-La Roche
Affective Disorder, Psychosis
Value of Gym-based Exercise Training for Young Adults Receiving Antipsychotic Medication: The Vega Trial
This is a multicentre, pragmatic, randomised controlled trial to estimate the effect of a 4-month gym-based exercise training program on 1) patient-rated personal recovery (primary outcome), 2) Health-related quality of life…
- Trial name
- Vega (NCT05461885)
- Testing
- Supervised exercise
- Where
- 4 sites in Denmark
- Volunteers
- 226 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Bipolar Disorder
A Randomized, Open-label Trial of Long-acting Injectable Risperidone Versus Oral Antipsychotic Medication in Patients With Bipolar Disorder
The purpose of this study is to determine the safety and effectiveness of a long-acting injectable formulation of risperidone in stable bipolar patients randomly switched from their current add-on oral antipsychotic (olanzapine…
- Trial name
- NCT00246246
- Testing
- risperidone
- Volunteers
- 48 people
- Sponsor
- Janssen-Ortho Inc., Canada
Sialorrhea
Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults
Multicenter, open-label, outpatient study of the safety and effectiveness of repeated doses of MYOBLOC over a 1-year duration in adult subjects with troublesome sialorrhea.
- Trial name
- OPTIMYST (NCT02610868)
- Testing
- MYOBLOC
- Where
- 35 sites in United States, Belarus and 1 more
- Volunteers
- 187 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Schizophrenia, Schizoaffective Disorder
Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome
The objective of this study is to determine the effect of various mood stabilizers (MS) on the insulin resistance syndrome (IRS; also called the metabolic syndrome) alone and in patients treated with antipsychotic drugs (APDs).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00288366
- Testing
- ziprasidone vs. aripiprazole, aripiprazole vs. ziprasidone
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Northwestern University
Stable Schizophrenia
A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia
The purpose of the study is to determine whether motivation/reward deficits observed in schizophrenia are attenuated and whether cognitive impairment associated with schizophrenia is improved by add-on TAK-041 administration to…
- Trial name
- NCT03319953
- Testing
- TAK-041, Second Generation Antipsychotics (SGA)
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- Neurocrine Biosciences
Schizophrenia
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
The objective of the study is to investigate the efficacy, safety and tolerability of four different doses of BI 409306 once daily compared to placebo given for 12 weeks in patients with schizophrenia on stable antipsychotic…
- Trial name
- NCT02281773
- Testing
- BI 409306 100 mg QD, BI 498306 50 mg QD, BI 498306 25 mg QD
- Where
- 43 sites in United States, Canada and 3 more
- Volunteers
- 518 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia
A Study of the Potential Effects of Trimethoprim on the Pharmacokinetics of ER OROS Paliperidone
The purpose of this study is to evaluate the effects of an organic cation transporter inhibitor, trimethoprim, on the pharmacokinetics of orally administered ER OROS paliperidone and to assess the safety and tolerability of the…
- Trial name
- NCT00892541
- Testing
- ER OROS paliperidone
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)
The primary purpose of this study is to evaluate the overall effect of caregivers receiving a study-provided caregiver psycho-education and skills training program on the number of treatment failures (psychiatric hospitalization…
- Trial name
- FIRST (NCT02600741)
- Testing
- Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate
- Where
- 34 sites in United States
- Volunteers
- 296 people
- Sponsor
- Janssen Scientific Affairs, LLC